

Robert P Edwards

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7357786/publications.pdf>

Version: 2024-02-01

81
papers

3,906
citations

236925

25
h-index

128289

60
g-index

81
all docs

81
docs citations

81
times ranked

8833
citing authors

#	ARTICLE	IF	CITATIONS
1	MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 855-871.	2.8	8
2	Phase I Trial Combining Chemokine-Targeting with Loco-Regional Chemoimmunotherapy for Recurrent, Platinum-Sensitive Ovarian Cancer Shows Induction of CXCR3 Ligands and Markers of Type 1 Immunity. <i>Clinical Cancer Research</i> , 2022, 28, 2038-2049.	7.0	16
3	Prospective Evaluation of Coronavirus Disease 2019 (COVID-19) Vaccine Responses Across a Broad Spectrum of Immunocompromising Conditions: the COVID-19 Vaccination in the Immunocompromised Study (COVICS). <i>Clinical Infectious Diseases</i> , 2022, 75, e630-e644.	5.8	65
4	Metformin and survival: Is there benefit in a cohort limited to diabetic women with endometrial, breast, or ovarian cancer?. <i>Gynecologic Oncology</i> , 2022, 165, 60-66.	1.4	4
5	Endometrial cancer risk factors in singapore chinese: A prospective cohort study. <i>Annals of Epidemiology</i> , 2022, , .	1.9	3
6	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 217-228.	2.5	12
7	Circulating CD14 + HLA-DR lo/hi monocyctic cells as a biomarker for epithelial ovarian cancer progression. <i>American Journal of Reproductive Immunology</i> , 2021, 85, e13343.	1.2	4
8	Gestational weight gain and risk of epithelial ovarian cancer. <i>Cancer Causes and Control</i> , 2021, 32, 537-545.	1.8	1
9	Same-day discharge after minimal invasive hysterectomy: Applications for improved value of care. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2021, 259, 140-145.	1.1	10
10	Do air gaps with image-guided vaginal cuff brachytherapy impact failure rates in patients with high-intermediate risk FIGO Stage I endometrial cancer?. <i>Brachytherapy</i> , 2021, 20, 512-518.	0.5	3
11	What is driving the decreased incidence of preterm birth during the coronavirus disease 2019 pandemic?. <i>American Journal of Obstetrics & Gynecology MFM</i> , 2021, 3, 100330.	2.6	27
12	Prevalence of intratumoral regulatory T cells expressing neuropilin-1 is associated with poorer outcomes in patients with cancer. <i>Science Translational Medicine</i> , 2021, 13, eabf8495.	12.4	16
13	Survival and recurrence after intraperitoneal chemotherapy use: Retrospective review of ovarian cancer hospital registry data. <i>Cancer Medicine</i> , 2020, 9, 7388-7397.	2.8	5
14	Immunotherapy Advances for Epithelial Ovarian Cancer. <i>Cancers</i> , 2020, 12, 3733.	3.7	24
15	Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. <i>British Journal of Cancer</i> , 2020, 123, 793-802.	6.4	35
16	Magnetic resonance imaging response in patients treated with definitive radiation therapy for medically inoperable endometrial cancer – Does it predict treatment response?. <i>Brachytherapy</i> , 2019, 18, 437-444.	0.5	8
17	Breastfeeding factors and risk of epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 153, 116-122.	1.4	22
18	It Is Time. <i>Annals of Surgical Oncology</i> , 2019, 26, 1963-1966.	1.5	0

#	ARTICLE	IF	CITATIONS
19	Joint exposure to smoking, excessive weight, and physical inactivity and survival of ovarian cancer patients, evidence from the Ovarian Cancer Association Consortium. <i>Cancer Causes and Control</i> , 2019, 30, 537-547.	1.8	16
20	Relationships Between a History of Abuse, Changes in Body Mass Index, Physical Health, and Self-Reported Depression in Female Bariatric Surgery Patients. <i>Bariatric Surgical Patient Care</i> , 2019, 14, 113-119.	0.5	5
21	Metabolic Syndrome in Endometrial Cancer Patients: Systematic Review. <i>Metabolic Syndrome and Related Disorders</i> , 2019, 17, 241-249.	1.3	9
22	MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. <i>Mayo Clinic Proceedings</i> , 2018, 93, 307-320.	3.0	22
23	Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. <i>British Journal of Cancer</i> , 2018, 118, 1123-1129.	6.4	15
24	Diagnosis and Treatment of Ovarian Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 943-964.	2.2	185
25	Together We Make a Difference. <i>Annals of Surgical Oncology</i> , 2018, 25, 1794-1796.	1.5	0
26	Helicase-Driven Activation of NF- κ B-COX2 Pathway Mediates the Immunosuppressive Component of dsRNA-Driven Inflammation in the Human Tumor Microenvironment. <i>Cancer Research</i> , 2018, 78, 4292-4302.	0.9	30
27	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. <i>PLoS ONE</i> , 2018, 13, e0197561.	2.5	9
28	Cost-effectiveness analysis of biopsy strategies for endometrial cancer diagnosis in women with postmenopausal bleeding: Pipelle sampling curette versus dilatation & curettage. <i>Gynecologic Oncology</i> , 2018, 150, 112-118.	1.4	15
29	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2473.	4.1	3
30	Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies. <i>International Journal of Cancer</i> , 2017, 140, 2422-2435.	5.1	25
31	Endometrial cancer associated biomarkers in bariatric surgery candidates: exploration of racial differences. <i>Surgery for Obesity and Related Diseases</i> , 2017, 13, 862-868.	1.2	6
32	Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2017, 146, 137-145.	1.4	4
33	Patient and provider factors associated with endometrial Pipelle sampling failure. <i>Gynecologic Oncology</i> , 2017, 144, 324-328.	1.4	20
34	Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium. <i>British Journal of Cancer</i> , 2017, 116, 1223-1228.	6.4	13
35	Dose-Response Association of CD8 ⁺ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. <i>JAMA Oncology</i> , 2017, 3, e173290.	7.1	260
36	History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report. <i>British Journal of Cancer</i> , 2017, 117, 1063-1069.	6.4	16

#	ARTICLE	IF	CITATIONS
37	History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1470-1473.	2.5	10
38	The Association of Peripheral Blood Regulatory T-Cell Concentrations With Epithelial Ovarian Cancer: A Brief Report. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 11-16.	2.5	9
39	Changes in inflammatory endometrial cancer risk biomarkers in individuals undergoing surgical weight loss. <i>Gynecologic Oncology</i> , 2017, 147, 133-138.	1.4	33
40	Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 626-631.	2.5	6
41	Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2016, 45, 884-895.	1.9	71
42	Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk. <i>Human Molecular Genetics</i> , 2016, 25, 3600-3612.	2.9	17
43	<i>PALB2</i> , <i>CHEK2</i> and <i>ATM</i> rare variants and cancer risk: data from COGS. <i>Journal of Medical Genetics</i> , 2016, 53, 800-811.	3.2	174
44	Chronic Recreational Physical Inactivity and Epithelial Ovarian Cancer Risk: Evidence from the Ovarian Cancer Association Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1114-1124.	2.5	32
45	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. <i>Human Genetics</i> , 2016, 135, 741-756.	3.8	19
46	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2016, 45, 1619-1630.	1.9	111
47	Regional Therapies for Advanced Cancer: Update for 2016. <i>Annals of Surgical Oncology</i> , 2016, 23, 1452-1453.	1.5	0
48	Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium. <i>British Journal of Cancer</i> , 2016, 115, 95-101.	6.4	39
49	Synergistic COX2 Induction by IFN γ and TNF α Self-Limits Type-1 Immunity in the Human Tumor Microenvironment. <i>Cancer Immunology Research</i> , 2016, 4, 303-311.	3.4	53
50	Assessment of Multifactor Gene-Environment Interactions and Ovarian Cancer Risk: Candidate Genes, Obesity, and Hormone-Related Risk Factors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 780-790.	2.5	10
51	The association between socioeconomic status and tumour stage at diagnosis of ovarian cancer: A pooled analysis of 18 case-control studies. <i>Cancer Epidemiology</i> , 2016, 41, 71-79.	1.9	20
52	Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 446-454.	2.5	9
53	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , 2016, 141, 386-401.	1.4	18
54	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. <i>Oncotarget</i> , 2016, 7, 69097-69110.	1.8	5

#	ARTICLE	IF	CITATIONS
55	Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. <i>Oncotarget</i> , 2016, 7, 72381-72394.	1.8	13
56	A targeted genetic association study of epithelial ovarian cancer susceptibility. <i>Oncotarget</i> , 2016, 7, 7381-7389.	1.8	7
57	Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. <i>Genetic Epidemiology</i> , 2015, 39, 689-697.	1.3	22
58	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. <i>Nature Genetics</i> , 2015, 47, 164-171.	21.4	221
59	Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1574-1584.	2.5	28
60	Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. <i>Gynecologic Oncology</i> , 2015, 136, 542-548.	1.4	15
61	Adipose-Derived Stems Cells and Their Role in Human Cancer Development, Growth, Progression, and Metastasis: A Systematic Review. <i>Cancer Research</i> , 2015, 75, 1161-1168.	0.9	100
62	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. <i>Nature Communications</i> , 2015, 6, 8234.	12.8	63
63	Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer. <i>Carcinogenesis</i> , 2015, 36, 1341-1353.	2.8	24
64	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. <i>Human Molecular Genetics</i> , 2015, 24, 5955-5964.	2.9	68
65	Not a Humbug: the evolution of patient-centred medical decision-making. <i>Evidence-Based Medicine</i> , 2015, 20, 193-197.	0.6	7
66	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). <i>Journal of Genetics and Genome Research</i> , 2015, 2, .	0.3	25
67	MUC1 Positive, Kras and Pten Driven Mouse Gynecologic Tumors Replicate Human Tumors and Vary in Survival and Nuclear Grade Based on Anatomical Location. <i>PLoS ONE</i> , 2014, 9, e102409.	2.5	12
68	Prognosis and Conditional Disease-Free Survival Among Patients With Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 4102-4112.	1.6	57
69	Stakeholder involvement is essential for patient centered applications of Google Trends research. <i>Surgery for Obesity and Related Diseases</i> , 2014, 10, 370-371.	1.2	2
70	An exploratory investigation of links between changes in adipokines and quality of life in individuals undergoing weight loss interventions: Possible implications for cancer research. <i>Gynecologic Oncology</i> , 2014, 133, 67-72.	1.4	11
71	In vitro chemoresponse in metachronous pairs of ovarian cancers. <i>Anticancer Research</i> , 2014, 34, 7191-6.	1.1	4
72	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 362-370.	21.4	326

#	ARTICLE	IF	CITATIONS
73	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 371-384.	21.4	493
74	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. <i>Nature Communications</i> , 2013, 4, 1628.	12.8	144
75	PGE ₂ -Driven Induction and Maintenance of Cancer-Associated Myeloid-Derived Suppressor Cells. <i>Immunological Investigations</i> , 2012, 41, 635-657.	2.0	131
76	Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. <i>Blood</i> , 2011, 118, 5498-5505.	1.4	431
77	A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 293-301.	4.2	57
78	Involvement of regulatory T cells and Th17 cells in ovarian endometriosis and ovarian epithelial tumors. <i>FASEB Journal</i> , 2008, 22, 1078.22.	0.5	0
79	Improved bowel function after gynecological surgery with epidural bupivacaine-fentanyl than bupivacaine-morphine infusion. <i>Canadian Journal of Anaesthesia</i> , 2000, 47, 406-411.	1.6	11
80	Expression of cytokine genes or proteins and signaling molecules in lymphocytes associated with human ovarian carcinoma. <i>International Journal of Cancer</i> , 1996, 68, 276-284.	5.1	81
81	Expression of cytokine genes or proteins and signaling molecules in lymphocytes associated with human ovarian carcinoma. <i>International Journal of Cancer</i> , 1996, 68, 276-284.	5.1	1